ArticleFrontiers in oncology2024
External validation of radiobiological models for local control prediction in lung cancer patients treated with stereotactic body radiation therapy.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The debate regarding the accuracy of radiobiological models for local control (LC) prediction in lung cancer patients undergoing stereotactic body radiation therapy (SBRT) remains unresolved. The study seeks to externally validate the predictive efficacy of radiobiological models using single-institutional SBRT database. Methods: The cohort comprised 153 patients diagnosed with primary or metastatic lung cancer who underwent SBRT. The study employed three radiobiological models to estimate the probability of 2-year LC, including the Liu model, Klement model, and Ohri model. Furthermore, the likelihood of 3-year LC was predicted using the Liu model, Klement model, Gucken model, and Santiago model. The performance of the prediction models was assessed through the AUC values of the receiver operating characteristic (ROC) curve and the calibration plots. Results: Local recurrence was observed in 38.6% of patients (59/153) within two years, and in 43.1% (66/153) within three years after the radiotherapy. The ROC curves indicated discriminative power for all the 2-year and 3-year models, with the exception of the Klement model. The Ohri model showed a significantly improved discriminative ability than the Klement model for 2-year prediction, while it was not statistically significant when compared to the Liu model. However, no significant differences were found among the four models in terms of 3-year LC prediction. The calibration plots, using the Hosmer-Lemeshow goodness-of-fit test, confirmed that the predicted probabilities of the models were in agreement with the actual observation with Conclusion: Considering the balance between prediction accuracy and model simplicity, it is recommended to utilize the Ohri model for 2-year LC prediction and either the Gucken model or Santiago model for 3-year LC prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.